Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
After a bumpy ride, the ride-hailing app is back in the good graces of investors. Plus: OpenAI, Google, Apple, Target, Moody's, Paramount, and Golden Dome.
Smoke that filled the cabin of a Delta flight as it took off from the Atlanta airport in February was so thick the led flight attendant had trouble seeing past the first row of passengers and the pilots donned oxygen masks as a precaution.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
